Literature DB >> 31317200

Impact of an interstitial lung disease service in the diagnosis and management of interstitial lung disease in Singapore.

Gin Tsen Chai1, Teck Choon Tan2, Yeong Shyan Lee3, Gregory Jl Kaw3, Khoon Leong Chuah4, Yi Jing Lim5, John Arputhan Abisheganaden1, Bernard Yh Thong6.   

Abstract

INTRODUCTION: The current gold standard for diagnosing interstitial lung disease (ILD) involves an ILD clinic evaluation, followed by discussion in a multidisciplinary meeting (MDM). However, there is a paucity of data on the impact of ILD MDMs on the diagnosis and management of ILDs in Southeast Asia. We studied the clinical impact of the ILD service on the diagnosis and management of ILDs at a university-affiliated tertiary hospital in Singapore.
METHODS: A single-centre retrospective review was done on 97 consecutive patients referred for evaluation to the ILD service from March 2016 to August 2017.
RESULTS: Mean age of the patients was 67 ± 11 years. Gender distribution was almost equal (52% male), with a majority of never-smokers (63%). Mean forced vital capacity (FVC) was 1.81 ± 0.66 L (66% ± 20% predicted). The three commonest referral diagnoses were ILD of uncertain classification (n = 38, 39%), connective tissue disease-associated ILD (CTD-ILD) (n = 24, 25%) and idiopathic pulmonary fibrosis (IPF) (n = 16, 17%). Following evaluation by the ILD service, there was a change of diagnosis in 60 (62%) patients and a change of management in 71 (73%) patients. The majority of consensus MDM diagnoses were IPF (n = 35, 36%), CTD-ILD (n = 30, 30%) and others (n = 15, 15%). There was a significant prognostic separation between the IPF and non-IPF diagnoses made following evaluation by the ILD service.
CONCLUSION: The ILD service allowed for more precise subtyping of various ILDs. This is particularly useful for IPF patients, who can benefit from antifibrotic therapies. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; interstitial lung disease; quality of health care

Year:  2019        PMID: 31317200      PMCID: PMC7905130          DOI: 10.11622/smedj.2019069

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  33 in total

Review 1.  Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go.

Authors:  Margaret L Salisbury; Jeffrey L Myers; Elizabeth A Belloli; Ella A Kazerooni; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

2.  Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty.

Authors:  Vincent Cottin
Journal:  Eur Respir J       Date:  2016-11       Impact factor: 16.671

3.  A cohort study of interstitial lung diseases in central Denmark.

Authors:  Charlotte Hyldgaard; Ole Hilberg; Audrey Muller; Elisabeth Bendstrup
Journal:  Respir Med       Date:  2013-09-20       Impact factor: 3.415

4.  Major trends in the manifestations and treatment of rheumatoid arthritis in a multiethnic cohort in Singapore.

Authors:  Ee Tzun Koh; Justina Wei Lynn Tan; Bernard Yu-Hor Thong; Cheng Lay Teh; Tsui Yee Lian; Weng Giap Law; Arul Earnest; Kok Ooi Kong; Tang Ching Lau; Yew Kuang Cheng; Hwee Siew Howe; Wern Hui Yong; Faith Li-Ann Chia; Hiok Hee Chng; Khai Pang Leong
Journal:  Rheumatol Int       Date:  2012-12-28       Impact factor: 2.631

5.  Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients.

Authors:  Gadi Schoenheit; Ian Becattelli; Alan H Cohen
Journal:  Chron Respir Dis       Date:  2011-08-19       Impact factor: 2.444

6.  Predictors of survival in systemic sclerosis (scleroderma).

Authors:  R D Altman; T A Medsger; D A Bloch; B A Michel
Journal:  Arthritis Rheum       Date:  1991-04

7.  Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.

Authors:  Evans R Fernández Pérez; Craig E Daniels; Darrell R Schroeder; Jennifer St Sauver; Thomas E Hartman; Brian J Bartholmai; Eunhee S Yi; Jay H Ryu
Journal:  Chest       Date:  2009-09-11       Impact factor: 9.410

8.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

9.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre.

Authors:  Nazia Chaudhuri; Lisa Spencer; Melanie Greaves; Paul Bishop; Anshuman Chaturvedi; Colm Leonard
Journal:  J Clin Med       Date:  2016-07-27       Impact factor: 4.241

View more
  3 in total

Review 1.  Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease.

Authors:  Nevins W Todd; Sergei P Atamas; Stella E Hines; Irina G Luzina; Nirav G Shah; Edward J Britt; Andrew J Ghio; Jeffrey R Galvin
Journal:  Expert Rev Respir Med       Date:  2022-01-31       Impact factor: 3.772

2.  IL-10/IL-10 receptor 1 pathway promotes the viability and collagen synthesis of pulmonary fibroblasts originated from interstitial pneumonia tissues.

Authors:  Hong Ye; Jiongwei Pan; Xiaoping Cai; Zhangyong Yin; Lu Li; Enhui Gong; Cunlai Xu; Hao Zheng; Zhuo Cao; Enguo Chen; Junfeng Qian
Journal:  Exp Ther Med       Date:  2022-06-15       Impact factor: 2.751

3.  A comprehensive assessment of environmental exposures and the medical history guides multidisciplinary discussion in interstitial lung disease.

Authors:  Neal Dodia; Diana Amariei; Blaine Kenaa; Doug Corwin; Lydia Chelala; E James Britt; Ashutosh Sachdeva; Irina G Luzina; Jeffrey D Hasday; Nirav G Shah; Sergei P Atamas; Teri J Franks; Allen P Burke; Stella E Hines; Jeffrey R Galvin; Nevins W Todd
Journal:  Respir Med       Date:  2021-02-11       Impact factor: 3.415

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.